Evaluation of a Proposed Testing Strategy for Laboratory-based Testing Using an HIV-1/2 Discriminatory Assay for HIV: Strategy 5 Data Needs. R. Boromisa,

Slides:

Advertisements

Similar presentations

Lab Experience with HIV RNA NAAT

Advertisements

Nick Curry, MD, MPH Infectious Diseases Prevention Section

Identifying HIV-2 Infections Using Differential Serological Assays HIV-1 (gp41)/HIV-2(gp36) (Select HIV or MultiSpot) by Testing HIV EIA Reactive Specimens.

Unit 6 Diagnosis & Follow-up of HIV Infection

HIV-1/HIV-2 PLUS O To detect HIV Antibody Groups M & O Genetic Systems™ HIV-1/HIV-2 PLUS O EIA   HIV Subtypes and Variants   Description of HIV-1/HIV-2.

Evaluation of a Three Rapid Test Algorithm for the Diagnosis of HIV Infection at Point-of-Care Rapid Testing Facilities: Strategy 4 Data Needs. R. Boromisa.

Performance of Bio-Rad Genetic Systems HIV-1/HIV-2 Plus O EIA Followed by Multispot or OraQuick Advance in a Dual Immunoassay HIV Testing Strategy Laura.

Comparative Performance of Dual 3rd Generation Immunoassays as a Potential Laboratory-Based HIV-1/2 Testing Strategy. B. Bennett, S. Fordan, O. David,

Evaluation of HIV Rapid Diagnostic Devices National STD Prevention Conference San Diego, CA 6 March 2002 Jennifer A. Malia, MS, MT WRAIR.

Resolution of Discordant Confirmatory Results on POC Reactive Rapid Tests: Florida’s Pilot Project HIV Diagnostics: New Developments and Challenges Feb.

Comparison of the HIV LIA vs WB on HIV-Negative Samples CDC-HIV Diagnostics Meeting “New Diagnostic Technologies” Dec 5-7, 2007 Dr. John Kim National Laboratory.

Supplemental Testing of Donors for HIV and HCV September 18, 2003 BPAC Meeting Robin Biswas, M.D. Indira Hewlett, Ph.D. FDA/CBER/OBRR/DETTD.

Rapid HIV Testing: 2005 Update Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Division of HIV/AIDS Prevention.

Validating 16 Member Pooled APTIMA® HIV-1 RNA testing Ethridge Steven F, Sullivan T, Bennett B, Parker M, Hanson D, Hilliard J, Hart C, Patel P Diagnostic.

HIV TESTING TECHNOLOGIES ELISA / WESTERN BLOT.

Comparing the New EIAs with Old Standbys: Florida Bureau of Laboratories Verification Data HIV Diagnostics: New Developments and Challenges Feb. 28, 2005.

Implementing screening for acute HIV infection in STD clinics already using rapid HIV antibody testing, New York City, 2007 Kathleen D. Gallagher, MPH.

Can Sequentially Reactive EIA’s Replace HIV-1 Western Blot Testing? Robert A. Myers Ph.D.

HIV Diagnostics and A New Testing Algorithm

6/03/031 Hepatitis C –Update Laboratory Issues Hema Kapoor MD. SM Virology Section Manager Bureau of Laboratories Michigan Department of Community Health.

12/6/07 v.3CDC 2007 HIV Diagnostic Conference1 Diagnosis of HIV-1 Infection in Phase I & II HIV Vaccine Trials RW Coombs 1, J Dragavon 1, B Metch 2, CJ.

CDC HIV Diagnostics Conference December 5-7, 2007 Sensitivity of OraQuick and Early Generation Enzyme Immunoassay (EIA) within a Pooled HIV Nucleic Acid.

Routine HIV Screening in Health Care Settings David Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine, Division.

Primary HIV Infection: the CDC study Pragna Patel, MD MPH Medical Epidemiologist Behavioral and Clinical Surveillance Branch DHAP, CDC February 28, 2005.

Epidemiology of HIV-2 infection in the U.S, Lata Kumar MS, MPH Richard Selik MD Division of HIV/AIDS Prevention National Center for HIV/AIDS,

Vironostika® HIV-1 Plus O Microelisa System

Diagnosis of HIV Infection

HIV-1/HIV-2 COMBINATION SCREENING AND OUTCOMES OF FOLLOW UP William R. Oleszko, Ph.D. Associate Director, Public Health Laboratory Department of Health.

Can a second rapid HIV test discriminate false positives as effectively as a Western Blot? The NJ Experience Evan M. Cadoff, MD Robert Wood Johnson Medical.

Alere TM HIV Combo Yuko Tamanoue, Product Development Department.

Jeffrey D. Klausner, MD, MPH Professor of Medicine and Public Health Attending Physician Ronald Reagan Medical Center Center for World Health and Division.

Evaluation of Commercially Available HIV Assays to Address Alternative Screening/Diagnostic Algorithms S. Michele Owen, Ph.D. Laboratory Branch Division.

Learning Objectives How to detect HIV antibodies/HIV infection?

Jeffrey D. Klausner, MD, MPH Professor of Medicine and Public Health Attending Physician Ronald Reagan Medical Center Center for World Health and Division.

NAT Yield from Real Time Testing of Organ Donors for HIV-1 RNA and HCV RNA Safer Organs and No False Positive Results Claudia Chinchilla-Reyes, MB(ASCP)1,

HIV Testing CDC power point edited by M. Myers

HIV Diagnosis: New Tests, New Algorithms and a New Focus Berry Bennett, MPH Retrovirology Section Chief FL Bureau of Public Health Laboratories, FDOH

Screening for Acute HIV-1 Infection at NYC DOHMH Public Health Laboratory William R. Oleszko, Ph.D. Associate Director, Public Health Laboratory Department.

Incorporation of the Aptima® HIV-1 RNA Assay into Serodiagnostic and Rapid Test Confirmation Testing Algorithms to Resolve Discordant Serological Results.

HIV Testing Quality Assurance and Quality Control

Results from the LA rapid testing study: What can they tell us about proposed point of care strategies? Kevin Delaney, MPH Division of HIV/AIDS Prevention.

E992750C 1 Replacement of HIV-1 p24 Antigen Screening with HIV-1 RNA Nucleic Acid Testing (NAT) for Whole Blood Donations S.L. Stramer, R.A. Porter, J.P.

J.L.K. Fletcher, S. Pinyakorn, M. de Souza, S. Akapirat, R. Trichavaroj, T. Pankam, E. Kroon, D. Colby, P. Prueksakaew, D. Suttichom, J.H. Kim, P. Phanuphak,

ICBS Master Panels for Kit Evaluation: HCV, HBV, and HIV ( Howard A. Fields, Ph.D. Susan Diaz, MPH Division of Viral Hepatitis Centers.

CLINICAL TRIAL OF THE HEMA-STRIP HIV RAPID TEST USING FINGERSTICK BLOOD, WHOLE BLOOD, PLASMA, AND SERUM Niel T. Constantine 1, Dan Bigg 2, Daniel Cohen.

Performance of rapid HIV tests used singly and in combination: Moving toward a point of care diagnosis. Kevin Delaney, MPH HIV Diagnostics: New Developments.

Figure 1 A Case Series of Discordant Laboratory Results with Statewide Rapid HIV Testing in New Jersey Eugene G Martin, PhD 1, Gratian Salaru, MD 1, Sindy.

Limitations of HIV Antibody Testing in a Population with High Incidence of HIV Infection Joanne Stekler 1,2, Paul D. Swenson 1,2, Robert W. Coombs 1, Joan.

HIV/AIDS is preventable and treatable, but is incurable.

RESULTS Rapid testing started at one publicly funded counseling and testing site in New Jersey on November 1, Through December 31, 2004, 48 sites.

Reducing the Delay: Can a Rapid HIV Test Discriminate False Positives as Effectively as a Western Blot – the NJ Experience Eugene G. Martin, Ph.D. *, Gratian.

New HIV Test Algorithms and Revised Adult HIV Case Report Form (DCH #1355) HIV Surveillance HIV/STD/VH/TB Epidemiology Section Bureau of Epidemiology Michigan.

DIAGNOSIS OF HIV INFECTION THE LABORATORY BY DR. K.BUJJIBABU.MD.

HIV diagnosis (general) ImmunoassaysNAT (PCR)

In the Footsteps of the WHO – Rapid HIV Testing in America Eugene Martin, Ph.D. *, Gratian Salaru, M.D. *, Sindy M. Paul, M.D., M.P.H.**, Evan Cadoff,

E001372A 1 ARC Experience with Indeterminate Blood Donors Susan L. Stramer, Ph.D. National Confirmatory Testing Laboratory American Red Cross.

HIV testing at the ICTC ICTC Team Training.

E A 1 Supplemental Testing for HIV-1 and HCV Blood Products Advisory Committee Meeting September 18, 2003 Susan L. Stramer, Ph.D. National Testing.

SPECIAL CONSIDERATIONS August

Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIVAIDS, Viral Hepatitis, STD,

HIV/AIDS is preventable and treatable, but is incurable.

Test 1Test 2Test 3Test 4Test 5Test 6 Sensitivity Specificity PPV NPV Performance.

 YEOH HUI SHIH –INTRODUCTION TO HIV  RAJAMANI- ELISA  TIEN WEI PING – WESTERN BLOTTING  YEO HUI YUN –OVERVIEW & CONCLUSION.

Incorporation of NAT into supplemental testing of HCV and HIV seroreactive donors Michael P. Busch representing Blood Systems Research Institute Blood.

California Clinical Laboratory Association

San Francisco Department of Public Health

Centers for Disease Control/Food and Drug Administration algorithm for second-generation HIV tests (20). †, an immunofluorescence assay (IFA) for HIV-1.

A CASE SERIES OF DISCORDANT LABORATORY RESULTS WITH RAPID HIV TESTING

Challenges for Blood Donor Confirmatory Testing Algorithms

Presentation transcript:

Evaluation of a Proposed Testing Strategy for Laboratory-based Testing Using an HIV-1/2 Discriminatory Assay for HIV: Strategy 5 Data Needs. R. Boromisa, J. Schwendemann, M. Parker, T. Sullivan. NEW YORK STATE DEPARTMENT OF HEALTH WADSWORTH CENTER ALBANY, NY

Description of Multispot (BioRad) HIV-1/HIV-2 Reactive Control Spot and Test Spots 1. Procedural control:Anti-human IgG (goat) 2. HIV-2 Peptide: Peptide representing the HIV-2 virus gp36 3. Recombinant HIV-1: Recombinant gp41 (gp41rDNA) 4. HIV-1 Peptide: Peptide representing the HIV-1 virus gp41

Results of 733 EIA HIV-1/2 reactive specimens tested using the HIV-1/2 discriminatory assay, January 2006 – September HIV-1 (-) HIV-2 (+) HIV-1 (+) HIV-2 (+) HIV-1 (-) HIV-2 (-) HIV-1 (+) HIV-2 (-) 0 Specimens 4 Specimens (0.5%) 4 HIV-1 only after Dilution 110 Specimens (15%) 18 WB ind 92 WB neg 619 Specimens (84.4%) 609 WB pos 9 WB ind 1 WB neg

Details of test results for 6 Multispot HIV-1/HIV-2 reactive specimens that were Western blot indeterminate and HIV-1 RNA positive. Specimen number EIA s/co Multispot result WB Band pattern ,1,1,0p24,p31,p51,*p66,*gp120/ ,4,3,0*p17,p24,*p31,*gp41,p51,p66, *gp120/ ,4,3,0p24,* gp41,*p51,p55,p66, gp ,4,3,0*p17,p24,*gp41,*p66,gp120/ ,4,3,0p17,p24,p66,gp120/ ,4,3,0p24,gp120/160 * Weakly reactive WB band

Specimen number EIA s/co Multispot Result WB band Pattern ,1,0,0p24,*p31,*p51,p66, gp120/ ,4,0,0*p24,*p55,*gp120/ ,4,0,0p24,p51 (QNS) ,2,2,0No Bands Details of test results for 4 HIV-1/HIV-2 reactive specimens that were Western blot indeterminate or negative and HIV-1 RNA negative or QNS. * Weakly reactive WB band

Details of test results for 110 Multispot HIV-1/HIV-2 nonreactive specimens that had detectable levels of HIV-1 RNA. Specimen number EIA s/co Multispot result WB Band pattern HIV-1 RNA ,0,0,0No BandsPositive ,0,0,0* p 24Positive * Weakly reactive WB band

Data needs for strategy 5: Questions 1 – 4. 1) Number and percentage of specimens reactive on an HIV-1/2 antibody screening test that are false negative on an HIV-1/2 discriminatory assay. There were 110 of 733 EIA HIV-1/2 reactive specimens (15.0%) that were nonreactive for both HIV-1 and HIV-2 on the HIV-1/2 discriminatory assay.

Data Needs for Stategy 5: (continued) 2) Number and percentage of specimens reactive for both HIV-1 and HIV-2 on an HIV-1/2 discriminatory assay that are: truly infected with HIV-1 only, truly infected with HIV-2 only, and true dual HIV-1/2 infections. There were 4 of the 733 EIA reactive specimens (0.5%) that were reactive for both HIV-1 and HIV-2 on the HIV-1/2 discriminatory assay. However, all were reactive for HIV-1 only upon conducting the manufacturer’s specified dilution analysis.

Data Needs for Strategy 5: (continued) 3) Number and percentage of specimens on an HIV-1/2 antibody screening test that are negative on an HIV-1 supplemental test but truly infected only with HIV-2. None of the 733 EIA HIV-1/2 reactive specimens (0%) were negative on HIV-1 supplemental tests that were truly infected with HIV-2.

Data Needs for Strategy 5: (continued) 4) Number and percentage of specimens reactive on two or more HIV-1/2 antibody screening tests that are truly infected with HIV-2. None of the 733 EIA HIV-1/2 reactive specimens (0%) were reactive for HIV-2 on the HIV-1/2 discriminatory assay.